Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.62 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.60 |
| ▸ | APP | P05067 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296622 | 0.92 | BACE1 (0.65) | BACE1BACE2KCNH2 | |
| SCHEMBL7941253 | 0.92 | BACE1 (0.65) | BACE1BACE2KCNH2 | |
| SCHEMBL12303290 | 0.90 | BACE1 (0.68) | BACE1BACE2APPCYP3A4KCNH2 | |
| SCHEMBL7941878 | 0.89 | BACE1 (0.62) | BACE1BACE2APP | |
| SCHEMBL7943954 | 0.86 | BACE1 (0.72) | BACE1BACE2KCNH2 | |
| SCHEMBL12301385 | 0.84 | BACE1 (0.73) | BACE1BACE2 | |
| SCHEMBL287519 | 0.84 | BACE1 (0.73) | BACE1BACE2 | |
| SCHEMBL12301386 | 0.84 | BACE1 (0.70) | BACE1BACE2KCNH2 | |
| SCHEMBL12301636 | 0.84 | BACE1 (0.64) | BACE1BACE2KCNH2 | |
| SCHEMBL7942229 | 0.84 | BACE1 (0.71) | BACE1BACE2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885APP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.